Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
10,935 total articles
DTE Energy ($DTE) is a broadly regulated utility with predictable cash flow and a growing DTE Vantage business that is capturing industrial and data-center demand. The stock trades at a market cap of roughly $31B with a 3.1% dividend yield and a trailing EPS of $6.07. Ahead of Q2 results, a measured long positioned at $148 targets $160 with a $140 …
Fortive has trimmed complexity through spin-offs and is now running as a higher-quality, cash-generative business focused on industrial reliability and advanced healthcare. Recent beat-and-raise results, near-$1.0B free cash flow, and an active $265M buyback in the last quarter create an actionable mid-term long trade. The setup is simple: buy near…
Norsk Hydro offers a compelling trade setup that captures structural decarbonization in aluminum while benefiting from long-term power security and a growing circularity business. Enter at $6.50, target $9.00, stop $5.20 for a long-term trade lasting roughly 180 trading days, with a medium risk profile tied to commodity cycles and power exposure.
Dover’s diversified industrial franchise looks buyable after a Q2 that reinforced steady cash generation and margin resilience. The stock has pulled back toward key support, RSI is near oversold, and fundamentals (FCF ~$1.14B, EPS ~$8.18, debt/equity 0.44) support a mid-term rebound. This trade idea offers an entry at $196.00, a stop at $186.00, an…
Digi Power X (DGXX) has demonstrable operational improvements - positive adjusted EBITDA, a cleaned-up balance sheet and over $30M in cash/crypto - yet the company has leaned heavily on equity markets to fund growth. For traders willing to accept dilution risk, a tactical long captures upside from AI/colocation deployments while sizing for a discip…
FANUY (FANUC ADR) shows meaningful industry and product-level momentum supported by AI/robotics partnerships, improving market visibility, and attractive macro tailwinds for automation. Technically the stock has pulled back below short- and mid-term moving averages, creating a tactical long opportunity with defined risk and clear catalysts over the…
Stride has been punished following platform implementation headaches and an earnings miss, but the core business is cash-generative, enrollment trends are improving, and the stock trades at a valuation that discounts much of the downside. This is a tactical long with defined entry, stop and target levels and a multi-horizon plan tied to upcoming ca…
ServiceNow's stock has been punished on AI disruption fears, but subscription growth, sizable free cash flow, and early AI monetization argue for a tactical long. This trade idea lays out a mid-term entry, stop and target with catalysts and risks.
Azul looks like a classic post-restructuring trade: a heavily discounted market cap ($1.57B), strong domestic demand tailwinds and a prior EBITDA run-rate cited at R$6.5bn give upside if management executes. But extreme historical volatility, residual leverage and low liquidity make this a high-risk, binary bet best sized small within a diversified…
DBV's Viaskin Peanut is moving through FDA interactions with no additional data requests and a planned BLA filing in Q3 2026. With a market cap near $825M, an ATM for up to $150M, and improving Phase 3 readouts, the stock looks set up for asymmetric upside over the next 3-6 months. This trade idea outlines entry, stop and target levels, catalysts t…
Taiwan Semiconductor (TSM) is at the center of a pricing standoff that can temporarily compress multiples but won't erase structural demand for AI-capable wafers. Q2 revenue growth of roughly 34% YoY and a material capex bump support a long-term constructive view. This trade idea buys weakness with a clear stop and a realistic target tied to re-tes…
QuantumScape is trading near its 52-week low after a very public reset of commercialization timelines. The company now has manufacturing B-sample cells, partnerships with automakers, and a market cap of roughly $3.15B versus an enterprise value near $3.5B. That positioning — progress on cell development plus the quality of funding to bridge to 2027…
Upstart is down more than 50% from its highs but still growing fast and returning to profitability. With a market cap near $2.6B, improving unit economics, and an oversold technical setup, this is a tactical long with defined risk controls for a 180-trading-day horizon.
General Motors rallied on Q2 results and lifted 2026 adjusted EBIT guidance to $14-16 billion. With free cash flow of roughly $14.4 billion, an EV/EBITDA around 11, and valuation below what blue-chips historically trade at on stable earnings, GM offers a pragmatic risk-reward for a 180-trading-day trade. I am initiating a long position with a clear…
KKR enters Q2 with two competing narratives: strong AUM growth and new secular initiatives (Helix digital infrastructure, insurance expansion) versus rich valuation metrics and negative free cash flow. This trade idea takes a measured long stance into the print, sized for a mid-term swing and defended by a tight stop if recurring-fee progress disap…
Super Micro (SMCI) has the scale and an AI-driven backlog, but recent margin compression, a massive $7B equity raise and negative free cash flow change the risk-reward. At a $21.1B market cap and stretched volatility, the stock is ripe for a mid-term short. Entry $31.00, stop $35.00, target $22.00 - plan duration: mid term (45 trading days).
Zevra (ZVRA) is a commercial-stage rare disease company with a newly approved therapy for Niemann-Pick disease type C and recurring royalty income. The stock trades at a single-digit P/E and below $800M market cap, creating a risk/reward setup for an initial long position. This idea outlines an entry, stop, target and the catalysts and risks that s…
Freeport-McMoRan (FCX) is a primary beneficiary of the ongoing copper supercycle. The company carries a large-scale, diversified copper portfolio, manageable leverage and meaningful free cash flow. With copper prices near record highs, FCX presents an actionable long trade for investors willing to hold through commodity-driven volatility.
ASML remains the linchpin of advanced chip fabrication as hyperscalers and foundries scale AI capacity. Recent guidance hikes and Q2 beats, combined with aggressive capacity plans, justify a tactical long. Valuation is rich but the moat and order backlog make a disciplined mid-term trade attractive.
UFP Technologies (UFPT) combines steady organic growth in single-use medical devices with healthy profitability and conservative leverage. At roughly $1.82B market cap and a trailing P/E near 27, the stock looks fairly valued today but merits an upgrade given accelerating medical demand, solid free cash flow of $69.7M, and multiple upcoming investo…
S&P Global just completed the Mobility spinoff and emerges leaner with a heavier weighting toward high-margin Ratings and Market Intelligence. Fundamentals (free cash flow $5.56B, ROE 15.3%, debt/equity 0.43) and an intact dividend make this a tactical long trade with defined risk. Technicals are mixed, so we'll enter near today's price with a stop…
Stride (LRN) suffered a steep selloff after platform implementation problems last year, but technical issues are largely resolved, enrollment is showing signs of recovery and valuation is attractive. We recommend a long trade at $84.00 with a $110.00 target over 180 trading days and a $72.00 stop loss, sized for a medium-risk allocation.
Andersons (ANDE) is a diversified agribusiness and renewables operator trading at a fair multiple relative to its earnings power. Recent institutional buying, a string of dividend increases, and improving renewable fuel performance justify a buy here without paying up for growth. This trade plan defines entry, stop and target levels across a 10-to-…
Ucore Rare Metals (UURAF) is showing mixed technicals: oversold readings and rising short activity sit alongside SMAs that still point lower. Market cap is modest at $309.7M but valuation multiples are unstable. This trade idea lays out a neutral/swing plan to capture a mean-reversion toward the 50-day SMA while respecting downside risk and structu…
Medpace's Q2 dynamics and corporate fundamentals justify a measured long position despite a legal overhang and elevated valuation. The company stands out with very high ROE, meaningful free cash flow and no debt; those facts, plus improving operational metrics, make a risk-managed buy for a 180-trading-day time horizon.
